Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.

[1]  O. Ringdén,et al.  Analysis of Tissues Following Mesenchymal Stromal Cell Therapy in Humans Indicates Limited Long‐Term Engraftment and No Ectopic Tissue Formation , 2012, Stem cells.

[2]  J. Kurtzberg,et al.  Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  J. Pidala,et al.  Glucocorticoid-refractory acute graft-versus-host disease. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  R. Deans,et al.  Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  M. MacMillan,et al.  The best endpoint for acute GVHD treatment trials. , 2010, Blood.

[6]  J. Kurtzberg,et al.  Treatment Of Steroid-Refractory Acute GVHD With Mesenchymal Stem Cells Improves Outcomes In Pediatric Patients; Results Of The Pediatric Subset In A Phase III Randomized, Placebo-Controlled Study , 2010 .

[7]  R. Herrmann,et al.  Prochymal Improves Response Rates In Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-GVHD) Involving The Liver And Gut: Results Of A Randomized, Placebo-Controlled, Multicenter Phase III Trial In GVHD , 2010 .

[8]  M. Selig,et al.  Immunomodulatory Function of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Type 1 Diabetes1 , 2009, The Journal of Immunology.

[9]  L. Isola,et al.  Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  M. A. Leroux,et al.  Treatment of inflammatory diseases with mesenchymal stem cells. , 2009, Inflammation & allergy drug targets.

[11]  G. Koren,et al.  Daclizumab therapy for children with corticosteroid‐resistant acute graft‐vs.‐host disease , 2009, Pediatric transplantation.

[12]  G. Dini,et al.  Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience , 2009, Bone Marrow Transplantation.

[13]  A. Kiani,et al.  Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium , 2009, Bone Marrow Transplantation.

[14]  J. Ryan,et al.  Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non‐redundant roles in human mesenchymal stem cell induction of CD4+CD25Highforkhead box P3+ regulatory T cells , 2008, Clinical and experimental immunology.

[15]  G. Dini,et al.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study , 2008, The Lancet.

[16]  R. Zhao,et al.  Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. , 2007, Transplantation proceedings.

[17]  L. Bouzas,et al.  Anti-tumor necrosis factor-a for the treatment of steroid-refractory acute graft-versus-host disease. , 2007, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[18]  T. Braun,et al.  Infliximab for GVHD therapy in children , 2007, Bone Marrow Transplantation.

[19]  M. Perales,et al.  Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease , 2007, Bone Marrow Transplantation.

[20]  H. Deeg,et al.  How I treat refractory acute GVHD. , 2007, Blood.

[21]  H. Deeg,et al.  A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. , 2007, Blood.

[22]  Hanns-Ulrich Marschall,et al.  Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease , 2006, Transplantation.

[23]  J. Klein,et al.  Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. , 2005, Blood.

[24]  Allen R. Chen,et al.  Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[26]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[27]  J. Klein,et al.  IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE , 1997, British journal of haematology.

[28]  R. Storb,et al.  A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. , 1990, Blood.

[29]  D. Weisdorf,et al.  Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. , 1990, Blood.

[30]  C. Briani,et al.  Polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes: not always a POEMS syndrome. , 2006, Haematologica.

[31]  D. Teachey,et al.  Daclizumab for children with corticosteroid refractory graft-versus-host disease , 2006, Bone Marrow Transplantation.